KLSE (MYR): GENTING (3182)
You're accessing 15 mins delay data. Turn on live stream now to enjoy real-time data!
Last Price
4.48
Today's Change
-0.01 (0.22%)
Day's Change
4.44 - 4.51
Trading Volume
5,379,100
Market Cap
17,330 Million
NOSH
3,877 Million
Latest Quarter
31-Dec-2023 [#4]
Announcement Date
29-Feb-2024
Next Quarter
31-Mar-2024
Est. Ann. Date
25-May-2024
Est. Ann. Due Date
30-May-2024
QoQ | YoY
-71.16% | 188.96%
Revenue | NP to SH
27,118,560.000 | 929,201.000
RPS | P/RPS
699.49 Cent | 0.64
EPS | P/E | EY
23.97 Cent | 18.65 | 5.36%
DPS | DY | Payout %
14.90 Cent | 3.33% | 62.16%
NAPS | P/NAPS
8.69 | 0.51
QoQ | YoY
52.23% | 409.83%
NP Margin | ROE
8.36% | 2.76%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Latest Audited Result
31-Dec-2022
Announcement Date
06-Apr-2023
Next Audited Result
31-Dec-2023
Est. Ann. Date
06-Apr-2024
Est. Ann. Due Date
28-Jun-2024
Revenue | NP to SH
27,118,560.000 | 929,201.000
RPS | P/RPS
699.49 Cent | 0.64
EPS | P/E | EY
23.97 Cent | 18.65 | 5.36%
DPS | DY | Payout %
14.90 Cent | 3.33% | 62.16%
NAPS | P/NAPS
8.69 | 0.51
YoY
409.83%
NP Margin | ROE
8.36% | 2.76%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Revenue | NP to SH
27,118,560.000 | 929,201.000
RPS | P/RPS
699.49 Cent | 0.64
EPS | P/E | EY
23.97 Cent | 18.65 | 5.36%
DPS | DY | Payout %
-
NAPS | P/NAPS
-
QoQ | YoY
-10.55% | 409.83%
NP Margin | ROE
8.36% | 2.76%
F.Y. | Ann. Date
31-Dec-2023 | 29-Feb-2024
Last 10 FY Result | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 27,118,560 | 27,118,560 | 27,118,560 | 22,383,714 | 13,529,534 | 11,564,060 | 21,616,543 | 20,852,973 | 20,019,594 | 18,365,805 | 18,100,356 | 18,216,498 | 4.51% | |
PBT | 3,567,037 | 3,567,037 | 3,567,037 | 1,265,064 | -970,782 | -1,526,452 | 4,582,582 | 3,418,398 | 4,312,215 | 5,459,561 | 3,445,997 | 4,262,349 | -1.95% | |
Tax | -1,299,805 | -1,299,805 | -1,299,805 | -1,220,643 | -442,305 | -547,525 | -901,487 | -974,529 | -1,069,360 | -981,731 | -848,320 | -1,116,223 | 1.70% | |
NP | 2,267,232 | 2,267,232 | 2,267,232 | 44,421 | -1,413,087 | -2,073,977 | 3,681,095 | 2,443,869 | 3,242,855 | 4,477,830 | 2,597,677 | 3,146,126 | -3.57% | |
- | ||||||||||||||
NP to SH | 929,201 | 929,201 | 929,201 | -299,909 | -1,369,646 | -1,024,141 | 1,995,823 | 1,365,581 | 1,445,298 | 2,120,580 | 1,388,012 | 1,496,133 | -5.15% | |
- | ||||||||||||||
Tax Rate | 36.44% | 36.44% | 36.44% | 96.49% | - | - | 19.67% | 28.51% | 24.80% | 17.98% | 24.62% | 26.19% | - | |
Total Cost | 24,851,328 | 24,851,328 | 24,851,328 | 22,339,293 | 14,942,621 | 13,638,037 | 17,935,448 | 18,409,104 | 16,776,739 | 13,887,975 | 15,502,679 | 15,070,372 | 5.71% | |
- | ||||||||||||||
Net Worth | 33,692,750 | 33,692,750 | 33,692,750 | 31,690,436 | 31,805,956 | 32,961,137 | 35,348,509 | 34,270,338 | 33,777,124 | 33,997,381 | 32,637,238 | 26,824,136 | 2.56% |
Dividend | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Div | 577,590 | 577,590 | 577,590 | 616,096 | 423,566 | 577,590 | 847,132 | 827,879 | 822,432 | 465,462 | 130,102 | 148,610 | 16.27% | |
Div Payout % | 62.16% | 62.16% | 62.16% | 0.00% | 0.00% | 0.00% | 42.45% | 60.62% | 56.90% | 21.95% | 9.37% | 9.93% | - |
Equity | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Worth | 33,692,750 | 33,692,750 | 33,692,750 | 31,690,436 | 31,805,956 | 32,961,137 | 35,348,509 | 34,270,338 | 33,777,124 | 33,997,381 | 32,637,238 | 26,824,136 | 2.56% | |
NOSH | 3,876,896 | 3,876,896 | 3,876,896 | 3,876,896 | 3,876,896 | 3,876,896 | 3,876,896 | 3,876,896 | 3,851,782 | 3,750,021 | 3,717,225 | 3,715,254 | 0.47% |
Ratio Analysis | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NP Margin | 8.36% | 8.36% | 8.36% | 0.20% | -10.44% | -17.93% | 17.03% | 11.72% | 16.20% | 24.38% | 14.35% | 17.27% | - | |
ROE | 2.76% | 2.76% | 2.76% | -0.95% | -4.31% | -3.11% | 5.65% | 3.98% | 4.28% | 6.24% | 4.25% | 5.58% | - |
Per Share | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RPS | 704.27 | 704.27 | 704.27 | 581.30 | 351.36 | 300.32 | 561.38 | 541.55 | 523.35 | 493.21 | 486.93 | 490.32 | 4.10% | |
EPS | 24.13 | 24.13 | 24.13 | -7.79 | -35.57 | -26.60 | 51.83 | 35.58 | 38.28 | 57.00 | 37.34 | 40.27 | -5.52% | |
DPS | 15.00 | 15.00 | 15.00 | 16.00 | 11.00 | 15.00 | 22.00 | 21.50 | 21.50 | 12.50 | 3.50 | 4.00 | 15.80% | |
NAPS | 8.75 | 8.75 | 8.75 | 8.23 | 8.26 | 8.56 | 9.18 | 8.90 | 8.83 | 9.13 | 8.78 | 7.22 | 2.15% |
Adjusted Per Share Value based on latest NOSH - 3,876,896 | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
RPS | 699.49 | 699.49 | 699.49 | 577.36 | 348.98 | 298.28 | 557.57 | 537.88 | 516.38 | 473.72 | 466.88 | 469.87 | 4.51% | |
EPS | 23.97 | 23.97 | 23.97 | -7.74 | -35.33 | -26.42 | 51.48 | 35.22 | 37.28 | 54.70 | 35.80 | 38.59 | -5.15% | |
DPS | 14.90 | 14.90 | 14.90 | 15.89 | 10.93 | 14.90 | 21.85 | 21.35 | 21.21 | 12.01 | 3.36 | 3.83 | 16.28% | |
NAPS | 8.6907 | 8.6907 | 8.6907 | 8.1742 | 8.204 | 8.5019 | 9.1177 | 8.8396 | 8.7124 | 8.7692 | 8.4184 | 6.919 | 2.56% |
Price Multiplier on Financial Quarter End Date | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date | 29/12/23 | 29/12/23 | 29/12/23 | 30/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 29/12/17 | 30/12/16 | 31/12/15 | 31/12/14 | - | |
Price | 4.62 | 4.62 | 4.62 | 4.48 | 4.67 | 4.46 | 6.05 | 6.10 | 9.20 | 8.00 | 7.34 | 8.87 | - | |
P/RPS | 0.66 | 0.66 | 0.66 | 0.77 | 1.33 | 1.49 | 1.08 | 1.13 | 1.76 | 1.62 | 1.51 | 1.81 | -10.59% | |
P/EPS | 19.15 | 19.15 | 19.15 | -57.52 | -13.13 | -16.77 | 11.67 | 17.20 | 24.35 | 14.05 | 19.66 | 22.03 | -1.54% | |
EY | 5.22 | 5.22 | 5.22 | -1.74 | -7.62 | -5.96 | 8.57 | 5.81 | 4.11 | 7.12 | 5.09 | 4.54 | 1.56% | |
DY | 3.25 | 3.25 | 3.25 | 3.57 | 2.36 | 3.36 | 3.64 | 3.52 | 2.34 | 1.56 | 0.48 | 0.45 | 24.55% | |
P/NAPS | 0.53 | 0.53 | 0.53 | 0.54 | 0.57 | 0.52 | 0.66 | 0.69 | 1.04 | 0.88 | 0.84 | 1.23 | -8.92% |
Price Multiplier on Announcement Date | ||||||||||||||
AQR | T4Q | 31/12/23 | 31/12/22 | 31/12/21 | 31/12/20 | 31/12/19 | 31/12/18 | 31/12/17 | 31/12/16 | 31/12/15 | 31/12/14 | CAGR | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Date | 29/02/24 | 29/02/24 | 29/02/24 | 23/02/23 | 24/02/22 | 25/02/21 | 27/02/20 | 27/02/19 | 27/02/18 | 23/02/17 | 23/02/16 | 26/02/15 | - | |
Price | 4.77 | 4.77 | 4.77 | 4.71 | 4.50 | 4.63 | 5.16 | 7.32 | 8.99 | 9.08 | 8.10 | 8.98 | - | |
P/RPS | 0.68 | 0.68 | 0.68 | 0.81 | 1.28 | 1.54 | 0.92 | 1.35 | 1.72 | 1.84 | 1.66 | 1.83 | -10.41% | |
P/EPS | 19.77 | 19.77 | 19.77 | -60.47 | -12.65 | -17.41 | 9.96 | 20.64 | 23.79 | 15.94 | 21.69 | 22.30 | -1.32% | |
EY | 5.06 | 5.06 | 5.06 | -1.65 | -7.90 | -5.74 | 10.04 | 4.84 | 4.20 | 6.27 | 4.61 | 4.48 | 1.36% | |
DY | 3.14 | 3.14 | 3.14 | 3.40 | 2.44 | 3.24 | 4.26 | 2.94 | 2.39 | 1.38 | 0.43 | 0.45 | 24.07% | |
P/NAPS | 0.55 | 0.55 | 0.55 | 0.57 | 0.54 | 0.54 | 0.56 | 0.82 | 1.02 | 0.99 | 0.92 | 1.24 | -8.63% |
PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.
NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.
Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.
All figures in '000 unless specified.
Viagra doesnt work, needs operation. Or else cut off directly. Replace the new one.
1 day ago
Posted by AngTayKor > 1 month ago | Report Abuse
Please remember history lesson becareful of 5.20 zone LKT waiting to dump. Price action of afternoon session dont look good.
--------
Red more likely means the whales sold off before LKT will start dumping.
-------
Read clearly. I said whales exited yesterday
--------
Traders left because the whales already left.
###################
Posted by Save > 3 weeks ago | Report Abuse
RM5 should not be a big resistance, 5.10-5.11 is. After 5.11 will be 5.40 based on TA as follows:
(TA technical analysis-Genting Berhad need confirmed breakout above the RM5.10 recent high to extend recovery towards RM5.40, with next hurdles at the 123.6%FP (RM5.60) and 138.2%FP (RM5.95) ahead, while the rising 100-day ma (RM4.56) provide uptrend support.
-------
Posted by Save > 3 weeks ago | Report Abuse
Expect almost at bottom if <4.70.....
************************
No offense here. I understand we are all here to share knowledge. Price Action VS Indicators, which trading method is more effective?
23 hours ago
Price action very important. But indicator also very good reference. Importantly is still the company fundamentals.
23 hours ago
I used indicators when I started trading. Nowadays I rarely use them.
Covid is already 4 years ago and all casinos fully reopened abt 3 years ago. More than enough time to recover back to pre-covid levels. This stock like maciam kena permanent covid virus. LKT ah LKT.... you better buck up!
23 hours ago
Hoping Q1 2024 result no more impairment or one time write off.
If without the above result should be very good compare to last quarter and last year.
Then end of May 2024 can go back to RM5.
23 hours ago
Impairments are on going, sometimes negatives more, sometimes less, sometimes even positives
22 hours ago
Beware of more kitchen sinking on the way. Dont surprise. For G. nothing is impossible. See today 10 richest tycoon list, Lkt almost 掉车尾.
20 hours ago
Let just forget about the Taurx nonsense. The share price will reflect it if it is so true.
20 hours ago
People just don’t get it! Genting share price has been underperforming since 2011 well before CV19! Why the underperformance? As i have highlighted, before there are many reasons. Poor governance generally, no change in CEO for last 20+ years despite poor performance. Highest remunerated CEO in Malaysia and other countries as well. Share dumping, in open market by key stakeholders, after dubious announcements, interested party related transactions where by poor performing investments held privately are sold to listed Genting entity, at inflated value, use of impairment charges to manipulate results as these charges often there is lot subjectivity, no promotion of company to generate interest via analysts meetings and holding capital markets day etc. Declaring high dividend when company cant afford it as owners needs cash to purchase other investments or to cover losses, eg like Genting Cruise. Only way price is going to rise any where near 8 RM is if TauRX becomes a reality! Otherwise Genting will continue to under perform even if sales and profits recover!
19 hours ago
Genting Group wont be allowed to list in US market as it won’t meet the regulators reporting requirements, and if it did it is more likely to get fined. If it really wants to make Genting attractive then it should look to list in US!
19 hours ago
Posted by AngTayKor > 1 week ago | Report Abuse
Posted by neohts > | Report Abuse
Just monitor TauRX progress.
AngTayKor, please provide us once you received any update on TauRX.
Very important. Do or die.
-------------
@Neohts, no doubt Taurx is the only hope for this stock to cross above rm10. HMTM confirm can work very well safely but there is "active placebo issue" under double-blinded trial environment. Taurx's success depends on other factors like the corrupted FDA's approval, etc. We may be proven right eventually abt Taurx's true potential in future but an investor can still lose money buying this stock along the way (price dropping back to 4.50, 4.30, 4.00 etc during bad selldowns). Currently, there are many investors that dont believe in the real potential of Taurx and view Taurx as a very small catalyst only. The stock market is a weighing machine in short term with stock price moving up and down. The market is always right so dont try to fight against the market.
-------------------------
Posted by lamkin > 2 hours ago | Report Abuse
Let just forget about the Taurx nonsense. The share price will reflect it if it is so true.
*************
@neohts, what I said earlier corect boh? Most people think Taurx is rubbish. There is a reason why ATK kena "seller's remorse" then bought back those shares that I sold earlier. Im waiting for Q4 UAE CA followed by deals at sideline to be activated. Even then, I believe GenB's share price will hardly reflect it unless LKT decide to lock in the USD billions in profit and sell out his 21% Taurx stake. The SWF can easily absorb LKT's entire 21% stake and they will be very happy to do so.
17 hours ago
@ATK Why would LKT sell if it's likely going to be the Golden Goose. Milk it for years to come la :p
17 hours ago
Posted by choysun > 4 hours ago | Report Abuse
@ATK Why would LKT sell if it's likely going to be the Golden Goose. Milk it for years to come la :p
------------
GenB currently sitting on over USD1B of unrealised profit on Taurx. After UAE CA when SWF deal's condition is met and activated, LKT can choose to sell his entire 21% stake for abt USD2B cash. Thats abt rm2.50/share of cash. But selling out early means lose future potential big upside. I think LKT probably wont sell any Taurx shares and will choose to hold his winning hand all the way to the end. For retail investor like me, I bet showhand until no money left. Hence, safer to sell a fraction first to take back all my vested capital after UAE CA.
12 hours ago
Daily Trading Participation
As at 16 April 2024
Participation Net (RM Mil)
Foreign -491
12 hours ago
Its normal for most investors here to think that Taurx is rubbish or scam when Maybank IB value Taurx at usd1b only, meaning GenB is sitting on losses for their Taurx investment.
12 hours ago
Is our own mistake, even if next month the share price go up to 5, we also won't sell thinking of TauRX. Then later down again.
Nobody know when TauRX could approved.
It is sad to see the price up and down from 5 to 4.46 so many time.
4 hours ago
@neohts, i believe in the potential of Taurx. But i have bought n sold GenB for so many rounds already. In fact last month i promptly reminded a few times here that the taurx news is just 24 mth result n not approval yet so dont get too carried away.
2 hours ago
Bought at 4.50 as expected after a long wait. Next waiting price is 4.00. Sure can get cos spent another 1B trying to get another casino licence. Once got 4.00, ready for the coming AGM
1 hour ago
Taurx is just play play. Dont get over excited over it. Approval is still a long way to go. Forget abt it
1 hour ago
Coming 4.40. Thailand open new casino. Sure hailat. Which tourist come Malaysia. Malaysia own people like to go Thailand also
1 hour ago
Posted by AngTayKor > 14 minutes ago | Report Abuse
@neohts, i believe in the potential of Taurx. But i have bought n sold GenB for so many rounds already. In fact last month i promptly reminded a few times here that the taurx news is just 24 mth result n not approval yet so dont get too carried away.
------------------
Even it is not approved, can the company sells this drug to make profit ?
The US is not a gentleman country, she will delay the final approval unless it is an US drug company.
Please advise.
Thank you.
1 hour ago
Don't be naive to believe Taurx will have any benefit to Genting, LKT will make way to pocket it to his private entity.
1 hour ago
Kan I say boss cannot one. Those who said G betapa bagus before now all sembunyi dalam hutan🤭
1 hour ago
Posted by Junichiro > 17 minutes ago | Report Abuse
TAURX is a UK company. Genting is one of its shareholders.
----------
Actually its a singapore company but base in UK
4 minutes ago
If no approval, of course much harder to sell the drug. However, HMTM is now available at HK under paid compassionate program. Taurx now applying to expand this program to other China territories like Macau guangdong region.
Unless LKT willing to sell out his 21% stake to SWF n crystalise the usd2b investment (probable value then) into cash after UAE CA, else its just a paper profit not even reflected in accounting books (probably still recorded at cost price).
Abt USA FDA, I believe its easier for FDA to approve weak problematic drugs developed by American pharmas like Biogen / Eli, than to reject a good drug with no side effects (especially after Tofersen's approval has opened a precedence for HMTM to follow using the AA pathway).
2 minutes ago
Ytl2023
U already join their club soon
1 day ago